S 1224
116th Congress
Senate
Health
Administrative law and regulatory procedures
Business ethics
Civil actions and liability
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Licensing and registrations
Public participation and lobbying
Stop STALLING Act
Everywhere this bill has been
5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 28, 2019
Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.
Jun 28, 2019
Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute and an amendment to the title. Without written report.
Jun 27, 2019
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Apr 29, 2019
Read twice and referred to the Committee on the Judiciary.
Apr 29, 2019
Introduced in Senate
Plain-English summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
What's happening now
Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.
Committees of jurisdiction
1
Cosponsors
1